Role of angiotensin II in the progression of diabetic nephropathy-therapeutic implications.
Wiecek
Andrzej
A
Department of Nephrology, Endocrinology and Metabolic Diseases, Silesian University Medical School, Katowice, Poland. awiecek@spskm.katowice.pl
Chudek
Jerzy
J
Kokot
Franciszek
F
D000804:Angiotensin II / Q000032:analysis / Q000378:metabolism*; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D015415:Biomarkers / Q000032:analysis; D003922:Diabetes Mellitus, Type 1 / Q000150:complications / Q000175:diagnosis; D003928:Diabetic Nephropathies / Q000188:drug therapy* / Q000209:etiology / Q000378:metabolism*; D018450:Disease Progression; D005260:Female; D006801:Humans; D008297:Male; D011379:Prognosis; D011945:Receptors, Angiotensin / Q000187:drug effects / Q000378:metabolism; D012084:Renin-Angiotensin System / Q000187:drug effects; D018570:Risk Assessment; D012680:Sensitivity and Specificity; D012720:Severity of Illness Index; D016896:Treatment Outcome
D000806:Angiotensin-Converting Enzyme Inhibitors; D015415:Biomarkers; D011945:Receptors, Angiotensin; D000804:Angiotensin II